Leping Li
Papers
1
Total Citations
4
H-Index
1
About
Leping Li is a leading surgical oncologist whose research focuses on optimizing perioperative care for gastric cancer patients, particularly those undergoing neoadjuvant chemotherapy (NACT) and minimally invasive surgery. Dr. Li’s major contributions center on the role of gut microbiota modulation in improving clinical outcomes after radical gastrectomy. Their most cited work, a multicenter randomized controlled trial protocol (GISSG2023-01 Study), investigates the effect of perioperative probiotic supplements on short-term outcomes in patients undergoing laparoscopic or robotic radical gastrectomy following NACT. This study addresses a critical gap in oncologic surgery—how to reduce postoperative complications and enhance recovery in a high-risk population. With 4 citations since its 2025 publication, the protocol has already garnered attention for its rigorous design and translational potential. Dr. Li’s research bridges surgical oncology, microbiome science, and enhanced recovery pathways, offering a novel, non-pharmacologic intervention to improve patient resilience. By targeting the gut–immune axis, their work may reshape perioperative protocols for advanced gastric cancer, underscoring a commitment to evidence-based, patient-centered innovation in gastrointestinal surgery.
Research Focus
Key Achievements
Top Papers
- 1